Is It Time to Sell MercadoLibre?
MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…
Sell
25
BIO Quote, Financials, Valuation and Earnings
Last price:
$221.01
Seasonality move
:
0.16%
Day range:
$220.59 - $227.00
52-week range:
$211.43 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.45x
P/B ratio:
0.90x
Volume:
246.3K
Avg. volume:
348.3K
1-year change:
-23.01%
Market cap:
$6B
Revenue:
$2.6B
EPS (TTM):
-$76.20
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $318.67, Bio-Rad Laboratories has an estimated upside of 43.51% from its current price of $222.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $260.00 representing 100% downside risk from its current price of $222.05.
Fair Value
-
According to the consensus of 4 analysts, Bio-Rad Laboratories has 43.51% upside to fair value with a price target of $318.67 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories has underperformed the S&P 500 by -4.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bio-Rad Laboratories reported revenues of $585.4M.
Earnings Growth
-
Bio-Rad Laboratories earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories reported earnings per share of $2.29.
Enterprise value:
5.6B
EV / Invested capital:
0.71x
Price / LTM sales:
2.45x
EV / EBIT:
--
EV / Revenue:
2.20x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
16.81x
Price / Operating cash flow:
18.78x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-20.89%
Net Income Margin (TTM):
-85.17%
Return On Equity:
-29.59%
Return On Invested Capital:
-25.43%
Operating Margin:
4.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.6B | $2.5B | $610.8M | $585.4M | |
| Gross Profit | $1.5B | $1.4B | $1.4B | $325.9M | $306M | |
| Operating Income | $390.6M | $320.5M | $248M | $44.6M | $23.7M | |
| EBITDA | -$65.5M | -$247.1M | -$2.5B | $540.5M | $133.5M | |
| Diluted EPS | -$6.43 | -$10.36 | -$76.20 | $13.45 | $2.29 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $3.3B | $3.3B | $3.1B | $3B | |
| Total Assets | $13.9B | $14.4B | $13.7B | $12.6B | $9.5B | |
| Current Liabilities | $609.9M | $648.3M | $589.6M | $466.2M | $506.6M | |
| Total Liabilities | $3.3B | $4.2B | $3.9B | $3.6B | $2.8B | |
| Total Equity | $10.6B | $10.2B | $9.8B | $9.1B | $6.7B | |
| Total Debt | $1.2M | $1.2B | $1.2B | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $242M | $346.6M | $515.3M | $69.8M | $129.9M | |
| Cash From Investing | -$361.9M | $47.6M | -$114.2M | -$43.1M | $2.9M | |
| Cash From Financing | -$212.4M | -$429.9M | -$316.5M | -- | -$97.7M | |
| Free Cash Flow | $125.1M | $185.4M | $332.1M | $29.6M | $95.5M | |
BIO
Sector
Market Cap
$6B
$33.6M
Price % of 52-Week High
57.23%
45.68%
Dividend Yield
0%
0%
Shareholder Yield
4.46%
-0.66%
1-Year Price Total Return
-23.01%
-38.85%
Beta (5-Year)
0.932
0.633
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$224.63
200-day SMA
Sell
Level
$303.53
Bollinger Bands (100)
Sell
Level
226.29 - 318.11
Chaikin Money Flow
Buy
Level
26.2M
20-day SMA
Sell
Level
$234.94
Relative Strength Index (RSI14)
Sell
Level
40.80
ADX Line
Sell
Level
18.13
Williams %R
Neutral
Level
-72.4227
50-day SMA
Sell
Level
$238.49
MACD (12, 26)
Sell
Level
-6.00
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
19.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8785)
Sell
CA Score
(Annual)
Level (-0.378)
Buy
Beneish M-Score
(Annual)
Level (-3.6873)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.345)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Stock Forecast FAQ
In the current month, BIO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $318.67.
-
Where Will Bio-Rad Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $318.67 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories?
Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $260.00.
-
What Is Bio-Rad Laboratories's Price Target?
The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $318.67 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.
-
What Is The Bio-Rad Laboratories Share Price Today?
Bio-Rad Laboratories was last trading at $221.01 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $222.05 per share.
-
How To Buy Bio-Rad Laboratories Stock Online?
In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Stock High Risk or High Reward?
EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…
Why Did Chase Coleman Buy TSM?
Billionaire Chase Coleman of Tiger Global Management has built a…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
80
GWRE alert for Jun 5
Guidewire Software [GWRE] is up 1.67% over the past day.
Buy
60
REVG alert for Jun 5
REV Group [REVG] is down 1.07% over the past day.
Buy
55
SIG alert for Jun 5
Signet Jewelers [SIG] is down 0.44% over the past day.
